Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2026)

Universe Pharmaceuticals has reported Cash & Equivalents for 7 years, with the latest figure at $27.6 million in Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (changed N/A YoY) and the FY2025 annual result came in at $33.6 million, up 13.88% from the prior year.
• Cash & Equivalents eased to $27.6 million in Q1 2026 per UPC's latest filing, from $33.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.7 billion in Q3 2022 and troughed at $8.9 million in Q1 2024.
• A 5-year average of $1.4 billion and a median of $28.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 70604.67% in 2022, then plunged 99.44% in 2024.
• Over 5 years, Cash & Equivalents stood at $5.7 billion in 2022, then decreased by 7.46% to $5.3 billion in 2023, then slumped by 99.44% to $29.5 million in 2024, then grew by 13.88% to $33.6 million in 2025, then decreased by 17.96% to $27.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $27.6 million, $33.6 million, and $29.5 million for Q1 2026, Q3 2025, and Q3 2024 respectively.